Delivery Order SPE2DB25D3110-SPE2DB25FTEKR
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $33,635.15 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 2, 2025, and represents a non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $24,257.92 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price arrangement. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,373.92 under a firm fixed-price contract type. This is a non-set-aside award issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The contractor will perform from its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial...
- The Defense Logistics Agency awarded a $28,849.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) with an ultimate completion date of June 20, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $5,149.68 firm fixed price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-unit bottles), with an ultimate completion date of October 20, 2025. This is a non-set-aside competitive award issued on October 17, 2025, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $11,537.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 1, 2025, with completion targeted for July 2, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $1,632.60 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $11,428.25 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count unit of use packaging) on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical supply transaction for federal medical procurement. The work will be performed at AmerisourceBergen's corporate headquarters...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEKRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,728.72 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, was placed on September 16, 2025, with an ultimate completion date of September 17, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate office location in the same city. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through December 2026 that supports military healthcare programs globally. The IDC enables the company to supply a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and related medical supplies to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. XELJANZ XR, a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, represents one of the specialized pharmaceutical products available through this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 9/16/25 |